GemPharmatech (SH:688046)2025-04-25 13:20Financial Performance - The company's operating revenue for Q1 2025 was ¥170,855,596.98, representing an increase of 8.76% compared to ¥157,087,264.43 in the same period last year[4]. - The net profit attributable to shareholders was ¥29,980,260.40, a slight increase of 1.70% from ¥29,479,404.17 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥25,108,916.52, reflecting a growth of 9.80% compared to ¥22,868,086.62 in the previous year[4]. - Total revenue for Q1 2025 reached ¥170,855,596.98, an increase of 8.8% compared to ¥157,087,264.43 in Q1 2024[16]. - Net profit for Q1 2025 was ¥29,980,260.40, slightly higher than ¥29,479,404.17 in Q1 2024, indicating a growth of 1.7%[17]. - Operating profit for Q1 2025 was ¥30,673,653.95, compared to ¥28,210,897.29 in Q1 2024, representing an increase of 8.7%[17]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,650,964,333.25, which is a 3.04% increase from ¥2,572,645,275.65 at the end of the previous year[5]. - The company's total current assets amounted to approximately ¥1.72 billion, slightly increasing from ¥1.71 billion as of December 31, 2024, reflecting a growth of 0.38%[13]. - The total non-current assets decreased from ¥1.01 billion to approximately ¥1.00 billion, indicating a decline of 1.1%[13]. - Total liabilities increased to ¥489,042,999.61 from ¥437,918,956.04, reflecting a rise of 11.7%[15]. - The company's equity attributable to shareholders rose to ¥2,161,921,333.64, compared to ¥2,134,726,319.61, an increase of 1.3%[15]. Cash Flow - The net cash flow from operating activities was -¥26,727,605.73, an improvement from -¥52,604,737.13 in the same period last year[4]. - Cash received from sales in Q1 2025 amounted to ¥125,542,405.66, a rise of 21.4% from ¥103,368,565.73 in Q1 2024[21]. - The net cash flow from operating activities was -$26.73 million, an improvement from -$52.60 million in the previous period[22]. - Cash inflow from investment activities totaled $375.41 million, down from $713.75 million year-over-year[22]. - The net cash flow from financing activities was $46.79 million, compared to a net outflow of -$16.04 million previously[23]. Research and Development - Research and development expenses totaled ¥20,170,418.65, down 12.31% from ¥23,002,751.52, with R&D expenses accounting for 11.81% of operating revenue, a decrease of 2.83 percentage points[5]. - Research and development expenses for Q1 2025 were ¥18,257,390.70, down from ¥23,002,751.52 in Q1 2024, indicating a decrease of 20.5%[17]. Inventory and Receivables - The company's accounts receivable increased from ¥350.81 million to ¥392.61 million, showing a growth of 11.9%[13]. - The company reported an increase in inventory from ¥54.20 million to ¥58.53 million, which is an increase of 8.5%[13]. Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to ¥3,199,528.58, which are closely related to its normal operations[6]. - The total non-recurring gains and losses for the period amounted to ¥4,871,343.88 after tax adjustments[7]. Other Information - The total number of ordinary shareholders at the end of the reporting period was 5,832[9]. - The company has no significant new product launches or technological developments mentioned in the conference call[12]. - There are no plans for market expansion or mergers and acquisitions discussed during the call[12]. - The company did not provide specific future guidance or performance outlook in the conference call[12].